ImmunityBio Inc 2026年季度报告

(Mark One) IMMUNITYBIO,INC. (Exact name of registrant as specified in its charter)_____________________________________ Registrant’s telephone number, including area code: (844) 696-5235_____________________________________ Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to suchfiling requirements for the past 90days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required to submitsuch files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). YesNo The number of shares of the Registrant’s common stock outstanding as of May5,2026 was 1,047,353,977 (excluding 163,800shares held by amajority owned subsidiary of ours which are treated as treasury shares for accounting purposes). IMMUNITYBIO, INC. AND SUBSIDIARIES QUARTERLY REPORT ON FORM10-QFOR THE QUARTER ENDED MARCH31,2026 TABLE OF CONTENTS Defined Terms Unless expressly indicated or the context required otherwise, the terms “ImmunityBio,” “thecompany,” “we,” “us,” and“our” in this Quarterly Report refer to ImmunityBio,Inc., a Delaware corporation, and, where appropriate, its subsidiaries. We havealso used several other terms in this QuarterlyReport, the unaudited condensed consolidated financial statements and accompanyingnotes included herein, most of which are defined below: PART I—FINANCIAL INFORMATION ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(Unaudited; in thousands, except share and per share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Balance Sheets (Continued)(Unaudited; in thousands, except share and per share amounts) The accompanying notes are an integral part of these condensed consolidated financial statements. ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Operations(Unaudited; in thousands, except per share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Comprehensive Loss(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders’ Deficit(Unaudited; in thousands, except share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Stockholders’ Deficit (Continued)(Unaudited; in thousands, except share amounts) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Continued)(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Continued)(Unaudited; in thousands) ImmunityBio, Inc. and SubsidiariesNotes to Unaudited Condensed Consolidated Financial Statements 1.Description of Business In these notes to unaudited condensed consolidated financial statements, the terms “ImmunityBio,” “the company,” “we,”“us,” and “our” refer to ImmunityBio, Inc. and its subsidiaries. Our Business ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generationimmunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectiousdiseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function andgenerating lasting immunological memory in patients. At the core of our strategy is the CancerBioShield platform, which is designedto stimulate critical lymphocytes, including natural killer (NK)cells, cytotoxic Tcells, and memory Tcells via our proprietary IL-15superagonist, ANKTIVA. Our CancerBioShield platform is anchored by this antibody-cytokine fusion protein and is complementedby a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additionalimmunomodulators intended to promote immunogenic cell death and support durable immune